Comparison of the diagnostic value of Ga-67 scan and F-18 DG PET in sarcoidosis patients

Comparison of the diagnostic value of Ga-67 scan and F-18 DG PET in sarcoidosis patients - Gallipet Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34129

Enrollment

Registered

2006-09-12

Start date

2006-11-27

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noncaseating granulomatous disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Active sarcoidosis

Exclusion criteria

Exclusion criteria: Pregnancy Younger than 18 years old Immunosuppressive therapy

Design outcomes

Primary

Measure	Time frame
The main study parameter is the uptake of Ga-67 citrate and F-18 DG in patients with active sarcoidosis. Ga-67 scan and F-18 DG PET will be evaluated by three independent nuclear physicians, who are blinded for the clinical data. Since all patients are symptomatic and histology is obtained at the time of inclusion, these findings are used a the gold standard for active sarcoidosis. Due to the absence of an internationally accepted gold standard for sarcoidosis activity, the specificity can not be determined. The results will be presented as sensitivity and inter observer agreement.	—

Measure

Time frame

The main study parameter is the uptake of Ga-67 citrate and F-18 DG in patients with active sarcoidosis. Ga-67 scan and F-18 DG PET will be evaluated by three independent nuclear physicians, who are blinded for the clinical data. Since all patients are symptomatic and histology is obtained at the time of inclusion, these findings are used a the *gold standard* for active sarcoidosis. Due to the absence of an internationally accepted gold standard for sarcoidosis activity, the specificity can not be determined. The results will be presented as sensitivity and inter observer agreement.

—

Countries

Netherlands

Outcome results